Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) - MSN MoneyCentral- Tasigna(R) (nilotinib) Effective in 77% of Patients Resistant or Intolerant to Prior Treatment in the Chronic (Early) Phase of Chronic Myeloid Leukaemia (CML)(1) - Highly Targeted Nature of Tasigna(R) Tackles the Root Cause of CML Whilst Providing Source: news.moneycentral.msn.com



